Calliditas Therapeutics (CALT) has released an update.
Calliditas Therapeutics has reported that its Phase 2b TRANSFORM trial for setanaxib, a treatment for primary biliary cholangitis (PBC), has successfully met its primary endpoint, demonstrating significant improvement in patients’ liver enzyme levels compared to placebo. Despite many patients already receiving multiple medications, setanaxib showed promising results with acceptable safety profiles, paving the way for further clinical trials in rare diseases. The company eagerly anticipates additional data from ongoing studies in idiopathic pulmonary fibrosis and Alport syndrome.
For further insights into CALT stock, check out TipRanks’ Stock Analysis page.
